|
|
|
| Clinical Effect of Ibutilide in Treating patients with Pre-excitation Syndrome and Atrial Fibrillation |
| SUN Shao-xi, TAN Wen-liang, LI Zhen-ci, et al |
| Department of Cardiology, Guangzhou First People's Hospital, Guangzhou 510180, China |
|
|
|
|
Abstract 【Objective】To investigate the clinical treatment and efficacy of ibutilide in patients with pre-excitation syndrome and atrial fibrillation. 【Methods】The diagnostic criteria of ECG for pre-excitation syndrome with atrial fibrillation are: rapid ventricular rate, absolute RR interval, wide QRS complex with initial delta wave. A retrospective analysis of the clinical data and treatment measures of 7 patients with pre-excitation syndrome and atrial fibrillation in Guangzhou First People's Hospital from February 2017 to June 2019. All patients were treated with Ibutilide fumarate injection. After the medication, all patients received pre-excitation of the side channel and (or) radiofrequency ablation of atrial fibrillation. Patients' sinus rhythm cardioversion and surgery after medication were recorded. 【Results】All 7 patients had good curative effect after intravenous injection of ibutilide, which could effectively convert pre-excitation syndrome patients with atrial fibrillation to sinus rhythm and reduce ventricular rate. In brief, 5 cases were converted to sinus heart rate, 1 case had a lower ventricular rate than before treatment, 1 case had no significant change in ventricular rate after amiodarone treatment and electrical cardioversion failed. However, the ventricular rate decreased significantly after ibutilide treatment. All patients were successfully treated with pre-excited side channel and/or radiofrequency ablation of atrial fibrillation.【Conclusion】Ibutilide can effectively convert the heart rhythm of patients with pre-excitation combined with atrial fibrillation, and can effectively reduce the ventricular rate of patients with pre-excitation combined with atrial fibrillation, which is beneficial to subsequent radiofrequency ablation treatment.
|
|
Received: 30 October 2020
|
|
|
|
|
|
[1] Kotsiou OS.A hiding in the lining: Irregular wide-complex tachycardia due to atrial fibrillation in Wolff-Parkinson-White syndrome[J]. Pacing Clin Electrophysiol, 2019,42(11):1499-1500.
[2] Hamada T, Hiraki T, Ikeda H, et al . Mechanisms for atrial fibrillation in patients with Wolff-Parkinson-White syndrome[J]. J Cardiovasc Electrophysiol, 2002,13(3):223-229.
[3] 何成毓,阳飞.预激综合征合并房颤的诊治分析[J].中西医结合心血管病杂志,2017,5(23):14-16.
[4] Centurion OA, Shimizu A, Isomoto S, et al . Mechanisms for the genesis of paroxysmal atrial fibrillation in the Wolff-Parkinson-White syndrome: intrinsic atrial muscle vulnerability vs. electrophysiological properties of the accessory pathway[J]. Europace, 2008,10(3):294-302.
[5] 杨雅舒,宋旭东,刘磊,等. 伊布利特的电生理作用及临床应用进展[J].昆明医科大学学报,2020,41(03):144-149.
[6] 张浩,夏雨,方丕华,等. 伊布利特对冷冻球囊消融术后仍为持续性心房颤动患者的转复疗效[J].中国心脏起搏与心电生理杂志,2019,33(06):518-521.
[7] Glatter KA, Dorostkar PC, Yang Y, et al . Electrophysiological effects of ibutilide in patients with accessory pathways[J]. Circulation, 2001,104(16):1933-1939.
[8] Nair M, George LK, Koshy SKG.Safety and efficacy of ibutilide in cardioversion of atrial flutter and fibrillation[J]. J Am Board Fam Med, 2011,24(1):86-92.
[9] 孙少喜,罗苑苑,李蘅,等. 伊布利特与胺碘酮对阵发性房颤复律的疗效比较[J].医学临床研究,2010,27(10):1801-1803.
[10] Gowda RM, Punukollu G, Khan IA, et al . Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety[J]. Am J Ther, 2003,10(4):259-263. |
|
|
|
2021, Vol. 38 
